BPMC — Blueprint Medicines Share News
0.000.00%
Last trade - 00:00- $8.37bn
- $8.18bn
- $508.82m
Brief: Blueprint Medicines Says Expect To Achieve $2 Billion In Ayvakit Revenue By 2030
U.S. RESEARCH ROUNDUP-Cisco, Freshpet, Nvidia
U.S. STOCKS ON THE MOVE-Zimmer Biomet, Shake Shack, Microsoft
U.S. STOCKS ON THE MOVE-XPO, Blueprint Medicines, AbbVie
Blueprint Medicines Corp reports results for the quarter ended in September 30 - Earnings Summary
Blueprint Medicines rises after lifting AYVAKIT's FY revenue forecast
Brief: Blueprint Medicines Q3 Net Income USD -56.276 Million Vs. IBES Estimate USD -60.9 Million
Blueprint Medicines Corp reports results for the quarter ended in January - Earnings Summary
Brief: Blueprint Medicines Q2 Net Income USD -49.994 Million Vs. IBES Estimate USD -80.6 Million
Blueprint Medicines Corp expected to post a loss of $1.29 a share - Earnings Preview
Brief: Blueprint Medicines Says On May 22, After Exceeding Milestone From Sales Of Ayvakit, Lenders Funded Tranche B Delayed Draw Term Loan Of $150.0 Million
Blueprint Medicines Corp reports results for the quarter ended in March - Earnings Summary
Brief: Blueprint Medicines Q1 Net Income USD 89.136 Million Vs. IBES Estimate USD -101.1 Million
Blueprint Medicines Corp expected to post a loss of $1.66 a share - Earnings Preview
Rigel Pharmaceuticals rises after acquiring US rights to lung cancer drug
U.S. STOCKS ON THE MOVE-Super Micro, Albemarle
U.S. STOCKS ON THE MOVE-Ginkgo, Jfrog, Alvotech
Blueprint Medicines up after beating Q4 estimates
Blueprint Medicines Corp reports results for the quarter ended in December - Earnings Summary